Fortitude Family Office’s Krystal Biotech KRYS Stock Holding History

Fortitude Family Office’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.83K	Buy	13 +2	+18%	+$598	﹤0.01%	1088
2026 Q1	$2.84K	Buy	11 +4	+57%	+$1.06K	﹤0.01%	1143
2025 Q4	$1.73K	Buy	7 +3	+75%	+$631	﹤0.01%	1237
2025 Q3	$706	Hold	4	–	–	﹤0.01%	1672
2025 Q2	$550	Buy	+4	New	+$588	﹤0.01%	1751

Other funds holding KRYS

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return

TAM

Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

CPIA

Cornell Pochily Investment Advisors Ithaca, New York $372M AUM 29.32% 1-Year Est. Return

Fortitude Family Office's KRYS Position: Q2 2026 in Review

Fortitude Family Office increased its Krystal Biotech (KRYS) stake by 18% in Q2 2026, buying an estimated $598 and bringing the position to 13 shares worth $4.83K. The position accounts for ﹤0.01% of the portfolio, ranked #1088.

Fortitude Family Office first reported a position in KRYS in Q2 2025 and has held it in 5 quarters since. 44 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Fortitude Family Office held 13 shares of Krystal Biotech worth $4.83K as of Q2 2026.
Fortitude Family Office bought 2 Krystal Biotech shares in Q2 2026, an estimated $598.
Krystal Biotech made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1088 holding.
Fortitude Family Office first reported a position in Krystal Biotech in Q2 2025 and has held it in 5 quarters since.
44 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.